^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    porustobart (HBM4003)

    i
    Other names: HBM4003, HBM 4003, HBM-4003
    Associations

    News

    Trials
    Company:
    Harbour BioMed
    Drug class:
    CTLA4 inhibitor, Treg cell depleter
    Related drugs:
    Associations

    News

    Trials
    2ms
    Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. (PubMed, J Immunother Cancer)
    HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 week demonstrated manageable safety in solid tumors and no new safety signal. Limited data demonstrated promising antitumor activity, especially in PD-1 treatment-naïve mucosal melanoma.
    P1 data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Loqtorzi (toripalimab-tpzi) • porustobart (HBM4003)
    over1year
    A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=65, Completed, Harbour BioMed US, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Sep 2022 --> Jan 2023
    Trial completion • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    porustobart (HBM4003)
    over2years
    A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, Harbour BioMed US, Inc. | Trial primary completion date: Jun 2022 --> Sep 2022
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    porustobart (HBM4003)
    over2years
    A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, Harbour BioMed US, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2023 --> Jun 2022
    Enrollment closed • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    porustobart (HBM4003)
    over3years
    A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=52, Recruiting, Harbour BioMed US, Inc. | N=30 --> 52 | Trial completion date: Feb 2022 --> Mar 2023 | Trial primary completion date: Oct 2020 --> Mar 2023
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    porustobart (HBM4003)
    over3years
    A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody (clinicaltrials.gov)
    P1, N=66, Not yet recruiting, Harbour BioMed (Guangzhou) Co. Ltd.
    Clinical • New P1 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • porustobart (HBM4003)